Crinetics PharmaceuticalsCRNX -0.47%41 Quick Ratio is 18.56 as of Mar. 2026, which is 13% above its 10-year median of 16.40. GuruFocus rates CRNX with a GF Score™ of 41/100 and a GF Value™ of $717.51 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,410 Biotechnology companies, Crinetics Pharmaceuticals ranks better than 91.06% on this metric.
Crinetics Pharmaceuticals has a quick ratio of 18.56. It generally indicates good short-term financial strength.
The historical rank and industry rank for Crinetics Pharmaceuticals's Quick Ratio or its related term are showing as below:
CRNX'
s Quick Ratio Range Over the Past 10 Years
Min: 8.73 Med: 16.4 Max: 31.02
Current: 18.56
During the past 10 years, Crinetics Pharmaceuticals's highest Quick Ratio was 31.02. The lowest was 8.73. And the median was 16.40.
CRNX's Quick Ratio is ranked better than 91.06% of 1410
companies
in the Biotechnology industry
Industry Median: 3.6
vs CRNX: 18.56
Crinetics Pharmaceuticals (NAS:CRNX) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Crinetics Pharmaceuticals Quick Ratio Related Terms
Crinetics Pharmaceuticals Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Crinetics Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Crinetics Pharmaceuticals Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Crinetics Pharmaceuticals's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Crinetics Pharmaceuticals's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Crinetics Pharmaceuticals's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Crinetics Pharmaceuticals (CRNX) has a Quick Ratio of 18.56 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Crinetics Pharmaceuticals and its competitors. This is 13% above median its historical median of 16.40. Over the past decade, Crinetics Pharmaceuticals' Quick Ratio has ranged from 8.73 to 31.02. According to the industry distribution chart, Crinetics Pharmaceuticals ranks #126 out of 1410 companies in the Biotechnology industry, placing it in the top 8.9%.
Is Crinetics Pharmaceuticals' Quick Ratio too high?
Crinetics Pharmaceuticals' current Quick Ratio of 18.56 is 13% above median its 10-year median of 16.40. Over the past 10 years, this metric has ranged from a low of 8.73 to a high of 31.02. The Biotechnology industry median Quick Ratio is 3.60. Crinetics Pharmaceuticals' value of 18.56 is 415.6% above this industry median. Based on the distribution chart, Crinetics Pharmaceuticals ranks #126 out of 1410 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Crinetics Pharmaceuticals has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Crinetics Pharmaceuticals' Quick Ratio compare to CPRX and NAMS?
According to the Biotechnology industry distribution chart, Crinetics Pharmaceuticals ranks #126 out of 1410 companies for Quick Ratio. This places Crinetics Pharmaceuticals in the top 9% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Crinetics Pharmaceuticals' value of 18.56 is 415.6% above this benchmark. Historically, Crinetics Pharmaceuticals' own Quick Ratio has ranged from 8.73 to 31.02 over the past decade. While the company's 10-year median is 16.40 vs. the industry median of 3.60, Crinetics Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Crinetics Pharmaceuticals's current Quick Ratio of 18.56 is 415.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Crinetics Pharmaceuticals and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Crinetics Pharmaceuticals's current Quick Ratio is 18.56, which is 13% above median its own 10-year median of 16.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crinetics Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Crinetics Pharmaceuticals (CRNX) is currently considered Possible Value Trap. The stock's GF Value™ is $717.51, compared to a current price of $42.02 — trading 94.1% below its estimated fair value. The current Quick Ratio is 18.56, which is 13% above median its 10-year median of 16.40 and 415.6% above the Biotechnology industry median of 3.60. Crinetics Pharmaceuticals' overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Crinetics Pharmaceuticals (CRNX), the current Quick Ratio is 18.56 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Crinetics Pharmaceuticals (CRNX) Overvalued in 2026?
Based on GuruFocus' analysis, Crinetics Pharmaceuticals stock appears to be undervalued.
The current stock price of $42.02 is trading 94.1% below its estimated GF Value™ of $717.51.
GuruFocus considers Crinetics Pharmaceuticals to be Possible Value Trap.
Key valuation signals for CRNX:
Quick Ratio: 18.56 (13% above median its 10-year median of 16.40)
GF Value™: $717.51 vs. price of $42.02 (94.1% below fair value)
Industry Position: 415.6% above the Biotechnology median (#126 of 1410)
No single metric tells the full story. See the CRNX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
41GF Score
Get the complete analysis for CRNX
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRNX has been successfully added to your 
